|
Jun 30
|
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
|
|
Jun 26
|
5 Revealing Analyst Questions From Amneal’s Q1 Earnings Call
|
|
Jun 25
|
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
|
|
Jun 12
|
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
|
|
Apr 17
|
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years
|
|
Apr 11
|
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
|
|
Apr 8
|
Amneal to Report First Quarter 2025 Results on May 2, 2025
|
|
Apr 7
|
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
|
|
Jan 23
|
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
|
|
Oct 1
|
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
|
|
Jul 29
|
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
|
|
Jul 27
|
In spite of recent selling, insiders still control 53% of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
|
|
Jun 5
|
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
|
|
May 6
|
Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)
|
|
May 4
|
Amneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
|
|
May 3
|
Amneal Reports First Quarter 2024 Financial Results
|
|
Feb 27
|
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
|
|
Jan 25
|
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
|
|
Jan 10
|
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
|
|
Dec 21
|
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
|